Heron Therapeutics Inc. (HRTX) Financial Statements (2025 and earlier)

Company Profile

Business Address 4242 CAMPUS POINT COURT, SUITE 200
SAN DIEGO, CA 92121
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

6/30/2025
MRQ
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:59,30080,40084,900157,600208,500391,000
Cash and cash equivalent25,80228,67715,36490,541105,13871,898
Short-term investments33,48151,73269,48867,039103,353319,074
Other undisclosed cash, cash equivalents, and short-term investments17(9)4820928
Receivables78,88160,13752,04935,49941,85039,879
Inventory, net of allowances, customer advances and progress billings53,16042,11054,57348,38241,90524,968
Inventory53,16042,11054,57348,38241,90524,968
Other undisclosed current assets17,6736,12713,91312,94221,94123,217
Total current assets:209,014188,774205,435254,423314,196479,064
Noncurrent Assets
Operating lease, right-of-use asset2,7875,4387,6459,82916,27713,754
Property, plant and equipment14,86320,16622,16023,73422,73719,618
Other noncurrent assets6,4838,12815,71117,720346346
Total noncurrent assets:24,13333,73245,51651,28339,36033,718
TOTAL ASSETS:233,147222,506250,951305,706353,556512,782
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities63,01854,31955,19344,92542,49154,541
Employee-related liabilities15,26313,59715,248
Accounts payable11,7093,2403,2253,8035252,758
Accrued liabilities51,30951,07951,96825,85928,36936,535
Debt     1,926
Other undisclosed current liabilities28,43925,36627,16226,13360,01240,238
Total current liabilities:91,45779,68582,35571,058102,50396,705
Noncurrent Liabilities
Long-term debt and lease obligation 149,700149,490149,284157,07814,56112,242
Long-term debt, excluding current maturities 149,700149,490149,284149,082  
Liabilities, other than long-term debt6153,0415,740   
Other liabilities615241241   
Operating lease, liability  2,8005,4997,99614,56112,242
Other undisclosed noncurrent liabilities 25,02624,263 (7,996)(14,561) 
Total noncurrent liabilities:175,341176,794155,024157,07814,56112,242
Total liabilities:266,798256,479237,379228,136117,064108,947
Equity
Equity, attributable to parent(33,651)(33,973)13,57277,570236,492403,835
Common stock1,5211,5031,1911,020913903
Additional paid in capital1,884,4091,870,5251,807,8551,689,9871,628,0701,568,317
Accumulated other comprehensive income (loss)1313(19)(6)25785
Accumulated deficit(1,919,594)(1,906,014)(1,795,455)(1,613,431)(1,392,748)(1,165,470)
Total equity:(33,651)(33,973)13,57277,570236,492403,835
TOTAL LIABILITIES AND EQUITY:233,147222,506250,951305,706353,556512,782

Income Statement (P&L) ($ in thousands)

6/30/2025
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Revenues144,285127,044107,67286,34688,638145,968
Cost of revenue
(Cost of Product and Service Sold)
(38,648)(65,105)(54,874)(46,021)(36,189)(61,619)
Gross profit:105,63761,93952,79840,32552,44984,349
Operating expenses(117,165)(172,554)(227,456)(258,153)(280,612)(295,043)
Operating income (loss):(11,528)(110,615)(174,658)(217,828)(228,163)(210,694)
Nonoperating income (expense)(2,052)56(7,366)(2,855)8855,945
Investment income, nonoperating 3,5503,3641,6384333,6337,259
Other nonoperating income (expense)430560(6,530)(878)(847)158
Interest and debt expense (6,032)(3,868)(2,474)(2,410)(1,901)(1,472)
Other undisclosed loss from continuing operations before equity method investments, income taxes      
Loss from continuing operations:(19,612)(114,427)(184,498)(223,093)(229,179)(206,221)
Loss before gain (loss) on sale of properties:(223,093)(229,179)(206,221)
Net loss:(19,612)(114,427)(184,498)(223,093)(229,179)(206,221)
Other undisclosed net income attributable to parent6,0323,8682,4742,4101,9011,472
Net loss available to common stockholders, diluted:(13,580)(110,559)(182,024)(220,683)(227,278)(204,749)

Comprehensive Income ($ in thousands)

6/30/2025
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Net loss:(19,612)(114,427)(184,498)(223,093)(229,179)(206,221)
Comprehensive loss:(19,612)(114,427)(184,498)(223,093)(229,179)(206,221)
Other undisclosed comprehensive income, net of tax, attributable to parent6,0323,9002,4612,1472,0731,644
Comprehensive loss, net of tax, attributable to parent:(13,580)(110,527)(182,037)(220,946)(227,106)(204,577)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: